SCHEMBL29573869

SCHEMBL29573869

CCNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NCC)cc(Cl)nc31)[C@@H]1OC(C)(C)O[C@@H]12

nearest known ligand 0.52

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ HRH2 P25021 1/20 0.52
▸ HTR5A P47898 1/20 0.52
▸ HSP90B1 P14625 3/20 0.49
▸ ADORA3 P0DMS8 13/20 0.47
▸ TMIGD3 P0DMS9 5/20 0.47
▸ HTR2B P41595 5/20 0.47
▸ ADORA1 P30542 12/20 0.42
▸ SLC6A3 Q01959 1/20 0.42
▸ HTR2C P28335 2/20 0.40
▸ ADORA2A P29274 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29573920 0.94 HRH2 (0.52) HRH2HTR5AHSP90B1ADORA3TMIGD3
SCHEMBL29574318 0.88 ADORA3 (0.53) HRH2HTR5AHSP90B1ADORA3TMIGD3
SCHEMBL26969055 0.86 HRH2 (0.49) HRH2HTR5AHSP90B1ADORA3TMIGD3
SCHEMBL29573437 0.85 HRH2 (0.51) HRH2HTR5AHSP90B1ADORA3TMIGD3
SCHEMBL29574766 0.85 HRH2 (0.51) HRH2HTR5AHSP90B1ADORA3TMIGD3
SCHEMBL29573974 0.84 HSP90B1 (0.69) HSP90B1ADORA3TMIGD3HTR2BADORA1
SCHEMBL29573475 0.84 HRH2 (0.49) HRH2HTR5AHSP90B1ADORA3TMIGD3
SCHEMBL29574457 0.82 ADORA3 (0.54) HRH2HTR5AADORA3TMIGD3HTR2B
SCHEMBL29573861 0.81 HRH2 (0.53) HRH2HTR5AHSP90B1ADORA3TMIGD3
SCHEMBL29573820 0.81 HRH2 (0.44) HRH2HTR5AHSP90B1ADORA3TMIGD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4196219-A1 A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE Biointervene, Inc. (US) 2023-06-21 — — EP disclosed
WO-2022040241-A1 A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE BIOINTERVENE, INC. (US) 2022-02-24 — — WO disclosed
Send feedback